Veristat agreed to acquire Certara’s regulatory and medical writing business for up to $135 million, expanding the contract services provider’s regulatory submission and documentation capacity. The deal adds more than 200 regulatory and medical writing specialists. Veristat said the acquisition is designed to improve global reach and service scalability without disrupting project timelines for clients, emphasizing back-office integration first over the first 60 to 90 days. Industry impact centers on execution for biotech and pharma sponsors facing tighter submission timelines and increased complexity, where medical writing throughput and regulatory expertise are often bottlenecks during late-stage development.